386 related articles for article (PubMed ID: 31692920)
1. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.
Biggioggero M; Becciolini A; Crotti C; Agape E; Favalli EG
Drugs Context; 2019; 8():212595. PubMed ID: 31692920
[TBL] [Abstract][Full Text] [Related]
2. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
6. Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Lee YH; Song GG
Z Rheumatol; 2020 Oct; 79(8):785-796. PubMed ID: 32055928
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Molecular Mechanism of Recognition of Selected Next-Generation Antirheumatoid Arthritis Inhibitors by Janus Kinase 1.
Sk MF; Jonniya NA; Roy R; Kar P
ACS Omega; 2022 Feb; 7(7):6195-6209. PubMed ID: 35224383
[TBL] [Abstract][Full Text] [Related]
9. JAK inhibitors for rheumatoid arthritis.
Kubo S; Nakayamada S; Tanaka Y
Expert Opin Investig Drugs; 2023 Apr; 32(4):333-344. PubMed ID: 37014106
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted.
Benucci M; Damiani A; Infantino M; Manfredi M; Lari B; Grossi V; Gobbi FL; Sarzi-Puttini P
Pharmacol Res; 2022 Sep; 183():106359. PubMed ID: 35907434
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial.
Shimizu T; Kawashiri SY; Morimoto S; Kawazoe Y; Kuroda S; Kawasaki R; Ito Y; Kiya R; Sato S; Yamamoto H; Kawakami A
Trials; 2023 Mar; 24(1):161. PubMed ID: 36869356
[TBL] [Abstract][Full Text] [Related]
12. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
13. Upadacitinib for the treatment of rheumatoid arthritis.
Serhal L; Edwards CJ
Expert Rev Clin Immunol; 2019 Jan; 15(1):13-25. PubMed ID: 30394138
[No Abstract] [Full Text] [Related]
14. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).
Parmentier JM; Voss J; Graff C; Schwartz A; Argiriadi M; Friedman M; Camp HS; Padley RJ; George JS; Hyland D; Rosebraugh M; Wishart N; Olson L; Long AJ
BMC Rheumatol; 2018; 2():23. PubMed ID: 30886973
[TBL] [Abstract][Full Text] [Related]
15. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
16. Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Rheumatology (Oxford); 2021 May; 60(Suppl 2):ii11-ii16. PubMed ID: 33950228
[TBL] [Abstract][Full Text] [Related]
17. Selective JAK inhibitors in development for rheumatoid arthritis.
Norman P
Expert Opin Investig Drugs; 2014 Aug; 23(8):1067-77. PubMed ID: 24818516
[TBL] [Abstract][Full Text] [Related]
18. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
Garufi C; Maclean M; Gadina M; Spinelli FR
Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
[TBL] [Abstract][Full Text] [Related]
19. Molecular Modeling Insights into Upadacitinib Selectivity upon Binding to JAK Protein Family.
Taldaev A; Rudnev VR; Nikolsky KS; Kulikova LI; Kaysheva AL
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056087
[TBL] [Abstract][Full Text] [Related]
20. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]